The partnership comprises a technology transfer of the current drug product manufacturing process for the Chikungunya Vaccine, with the option to transfer the drug substance process at a later stage
IVI is advancing clinical development of BBV87 through a phase II/III randomised, controlled trial to evaluate the safety and immunogenicity of a 2-dose regimen of BBV87 chikungunya vaccine
